LORANAX

This brand name is authorized in Nigeria.

Active ingredients

The drug LORANAX contains one active pharmaceutical ingredient (API):

1	Loratadine UNII 7AJO3BO7QN - LORATADINE
	Loratadine is a tricyclic antihistamine with selective, peripheral H1-receptor activity. Loratadine has no clinically significant sedative or anticholinergic properties in the majority of the population and when used at the recommended dosage.
	Read more about Loratadine

Packages

This drug has been approved in Nigeria as follows:

Identifier	Form	Presentation	Description	Approval
A4-0469	Tablet	LORANAX TABLET LORATIDINE 10MG TAB 10 mg 10 X 10	28 CMS-PP-348377 LORANAX TABLET LORATIDINE 10MG LORATIDINE,LACTOSE MONOHYDRATE, MAIZE STARCH, COLLOIDAL SILICON DIOXIDE, SODIUM STARCH GLYCOLATE. CROSS CARMELLOSE SODIUM, MAGNESIUM STEARATE, TALCUM, PURIFIED WATER, P.V.P.K-30, MICROCRYSTALLINE CELLULOSE A4-0469 Drugs Imported Products 10X10 OTC 8/14/2023 GREENLIFE PHARMACEUTICALS LIMITED, 35A, ASSOCIATION AVENUE, ILUPEJU, LAGOS 17378995 greenlife.regulatory@yahoo.com RELAX BIOTECH PVT.LTD., 862/1, G.I.D.C., MAKARPURA, BARODA – 390 010, GUJARAT, INDIA, India	31/01/2024

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
R06AX13	Loratadine	R Respiratory system → R06 Antihistamines for systemic use → R06A Antihistamines for systemic use → R06AX Other antihistamines for systemic use
Discover more medicines within R06AX13

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
NG	Registered Drug Product Database	A4-0469